According to the Zhongtong Finance APP, Telix Pharmaceuticals submitted its initial public offering application to the US Securities and Exchange Commission last Friday, planning to raise up to $100 million. The company is currently listed on the Australian Securities Exchange and plans to list on NASDAQ with the stock code "TLX".

The company is a commercial-stage Australian biotechnology company developing therapeutic and diagnostic radiopharmaceuticals.

Telix Pharmaceuticals focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals, with a portfolio of candidates in areas such as urological oncology (prostate and kidney), neuro-oncology (glioblastoma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its prostate cancer product portfolio includes Illuccix, a commercially available 68-gallium-labeled prostate-specific membrane antigen prostate cancer imaging agent. Illuccix was approved by the Australian TGA and FDA in 2021 and by Health Canada in 2022.

This company, headquartered in North Melbourne, Australia, was established in 2017 and had revenues of $385 million for the 12 months ended March 31, 2024. Telix Pharmaceuticals submitted their application in secret on January 25, 2024. Jefferies Financial, Morgan Stanley, Truist Securities, and William Blair are joint book-running managers for the transaction. The company has not yet disclosed pricing terms.